MUC1 and neoplasm: Finally, there are ongoing studies of Tumor lysate-based DC vaccines, which demonstrated an early invitro efficacy, while MUC1-loaded DC vaccine used as adjuvant treatment after the resection of biliary tract and pancreatic malignancies did not exert anti-MUC-1 antibody responses [159,160].